Megalotect Cp (Human Cytomegalovirus Immunoglobulin)

The immunoglobulin provides passive immunity by delivering high‑titer antibodies that specifically bind to CMV particles. These antibodies neutralize the virus, block its entry into host cells, and promote clearance by the recipient’s immune system, thereby limiting viral replication and disease.

The dosing regimen for Megalotect Cp is individualized and determined by the prescribing clinician based on factors such as the patient’s weight, CMV serostatus, type of transplant, and clinical condition. Exact dosage and infusion rate should follow the prescriber’s instructions and local guidelines.

Safety data for Megalotect Cp in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing individuals.

To order Megalotect Cp, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Megalotect Cp offers passive immunization, whereas antiviral agents such as valganciclovir provide active viral suppression. Immunoglobulin therapy can be advantageous for prophylaxis or when antiviral resistance is a concern, but it requires intravenous administration and careful monitoring for infusion‑related reactions.

Megalotect Cp must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Prior to use, inspect the solution for particulate matter or discoloration and allow it to reach room temperature if required by the infusion protocol.

Megalotect Cp is administered as an intravenous infusion. The infusion rate and total volume are determined by the prescriber, often starting slowly to assess tolerance and then increasing as needed. Administration should occur under medical supervision with facilities to manage potential infusion reactions.

The most serious risks include severe allergic reactions such as anaphylaxis, thromboembolic events, acute renal dysfunction, aseptic meningitis, and hemolysis. Immediate medical attention is required if any signs of these reactions appear during or after infusion.

Megalotect Cp should be avoided in patients with a known severe IgA deficiency, a history of anaphylactic reactions to immunoglobulin products, or those who have demonstrated hypersensitivity to any component of the formulation. Clinicians should also exercise caution in patients with uncontrolled renal impairment.